Skip to main content
. 2023 Oct 2;29(10):2570–2576. doi: 10.1038/s41591-023-02589-w

Fig. 5. Duration of treatment and molecular response for patients achieving CR or sCR.

Fig. 5

MRD status was assessed by next-generation sequencing at a sensitivity of 1 × 10−5 in accordance with IMWG criteria. Evaluable patients had a dominant VDJ or VJ sequence at baseline and confirmed response of CR or better. Black asterisk indicates ‘not evaluable’. u, unconfirmed.